The UK and US have forged a significant commercial pact that will keep no duties on British medicine shipments entering the US market.
Key Provisions of the Accord
As part of the deal, the UK has pledged to boost funding on medicines through the National Health Service (NHS). This pledge secures that tariffs on these crucial exports will remain at zero for a timeframe of three years.
This deal is in response to recent warnings to dramatically increase duties on patented pharmaceutical imports, with potential rates floated reaching one hundred percent.
"This agreement between the UK strengthens the global environment for innovative medicines and introduces much-needed balance to transatlantic pharmaceutical trade," a statement noted.
Commercial Importance
Pharmaceuticals are one of the UK's biggest export categories to the US, which is easily the largest market for large British pharmaceutical firms.
Trade data show that in the one-year period prior to the third quarter, the UK shipped drugs worth billions to the US. This amount made up a significant portion of all goods exports in that period.
"This deal safeguards jobs, increases investment and paves the way for the UK to become a global hub for life sciences," the Business and Trade Secretary commented.
Key NHS Changes
The deal involves several specific pledges from the United Kingdom:
- Price Threshold Increase: The UK will raise the price threshold at which it judges new therapies to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a goal to double total NHS spending on medicines from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Refund Ceiling: The amount drug companies must pay back to the NHS to control costs will be limited at fifteen percent. Last year, refunds exceeded 20%.
Industry Background
This agreement comes amid a ongoing row between the drug companies and the UK government over medicine costs and NHS adoption.
These tensions were heightened by arguments that American patients were paying significantly more for the identical medicines than consumers in the UK and Europe.
In recent months, several large manufacturing plans in the UK have been paused or scrapped, while substantial investments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS must invest a greater share on medicines, noting that its budget allocation on drugs had declined as a percentage of its resources over the previous ten-year period.
